Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor α-Independent Mechanism
Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor α-Independent Mechanism
复制标题
DOI：
10.1124/mol.108.052928
复制
发表时间：
2009-04-01
影响因子：
3.6
通讯作者：
Aoyama, Toshifumi
中科院分区：
文献类型：
--
作者：
Nakajima, Takero;Tanaka, Naoki;Aoyama, Toshifumi
根据啮齿动物研究的结果，苯扎贝特在人体中的降血糖作用归因于过氧化物酶体增殖物激活受体（PPAR）α激活。然而，在常规啮齿动物实验中使用的苯扎贝特剂量通常高于临床使用的剂量（>= 50对
The triglyceride-lowering effect of bezafibrate in humans has been attributed to peroxisome proliferator-activated receptor (PPAR) alpha activation based on results from rodent studies. However, the bezafibrate dosages used in conventional rodent experiments are typically higher than those in clinical use (>= 50 versus